Cite
APA Citation
Johnson, M., Galsky, M., Barve, M., Goel, S., Park, H., Du, B., Mu, S., Ramakrishnan, V., Wood, K., Wang, V., & Lakhani, N. (n.d.). 421PPreliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095487487.0x000038